The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII ...

Johnson & Johnson's financial results are generally ... a new law in the U.S. that gives Medicare the power to negotiate drug prices. The first round of negotiations will target three of the ...

neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release. “For too long, health care providers have had few options to offer patients much-needed symptom ...